A preparation from soy called Bowmann-Birk Inhibitor Concentrate (BBIC) appears to dramatically improve mobility and walking of an animal model with multiple sclerosis, and neurologists say that the substance may be useful as a single therapy, or in conjunction with conventional therapies used in treating MS, such as beta-interferon.
Further analysis revealed that the central nervous systems of animals that received BBIC showed “significantly less inflammation and demyelination” than those that didn’t receive the therapy. “It’s the first time that BBIC has been used in an EAE model and has shown significant disease suppression, and we hope it can eventually be used in humans,” says Dr. Rostami. His group’s next step is to design clinical trials in humans.
The researchers speculate that BBIC works by suppressing the immune response to some extent, or by inhibiting proteases responsible for the inflammation and demyelination in MS. They study has been published in the journal Multiple Sclerosis.